Medtronic landed a significant win with the announcement of an FDA win for its Resolute Integrity drug-eluting stent, the first device on the U.S. market cleared for patients with coronary artery disease as well as diabetes.
Diabetic patients make up about ⅓ of all those with CAD, and they represent a difficult-to-treat population.